This company has been acquired
Elevation Oncology (ELEV) Stock Overview
An oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ELEV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Elevation Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$3.09 |
| 52 Week Low | US$0.22 |
| Beta | 1.5 |
| 1 Month Change | -4.25% |
| 3 Month Change | -2.90% |
| 1 Year Change | -87.37% |
| 3 Year Change | -70.33% |
| 5 Year Change | n/a |
| Change since IPO | -96.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELEV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.7% | -4.1% | 1.2% |
| 1Y | -87.4% | 26.5% | 27.0% |
Return vs Industry: ELEV underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: ELEV underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| ELEV volatility | |
|---|---|
| ELEV Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ELEV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ELEV's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 34 | Tammy Furlong | elevationoncology.com |
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It’s lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors. The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors.
Elevation Oncology, Inc. Fundamentals Summary
| ELEV fundamental statistics | |
|---|---|
| Market cap | US$21.63m |
| Earnings (TTM) | -US$47.99m |
| Revenue (TTM) | n/a |
Is ELEV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELEV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$47.99m |
| Earnings | -US$47.99m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 66.9% |
How did ELEV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/24 17:13 |
| End of Day Share Price | 2025/07/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elevation Oncology, Inc. is covered by 4 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Michael King | H.C. Wainwright & Co. |